Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.53 |
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 3/20 | 0.51 |
| ▸ | PTPRB | P23467 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56477 | 0.93 | TGFBR1 (0.59) | TGFBR1GPR119LIMK2STSPTPRB | |
| SCHEMBL56220 | 0.83 | STS (0.56) | TGFBR1GPR119APLNRSTSJAK2 | |
| SCHEMBL18919731 | 0.81 | USP30 (0.53) | TGFBR1GPR119LIMK2STSPTPRB | |
| SCHEMBL28622272 | 0.81 | STS (0.47) | TGFBR1GPR119APLNRSTSJAK2 | |
| SCHEMBL24762621 | 0.81 | FPR2 (0.53) | TGFBR1GPR119STSPTPRBPTPN11 | |
| SCHEMBL18423817 | 0.81 | STS (0.61) | TGFBR1GPR119STSPTPRBPTPN11 | |
| SCHEMBL18423783 | 0.81 | GPR119 (0.59) | TGFBR1GPR119STSPTPN2PTPN1 | |
| SCHEMBL30158343 | 0.80 | TGFBR1 (0.51) | TGFBR1GPR119STSPTPN2PTPN1 | |
| SCHEMBL25171258 | 0.80 | TGFBR1 (0.51) | TGFBR1GPR119STSPTPN2PTPN1 | |
| SCHEMBL22280127 | 0.79 | EPHX1 (0.46) | GPR119APLNRSTSPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007050522-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203122-A1 | Derivatives for modulation of ion channels | TRPV1, TRPA1, TRPV2 | TGFBR1 4567/4885GPR119 585/4885APLNR 760/4885 |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | TRPV1, TRPA1, TRPV2 | TGFBR1 4567/4885GPR119 585/4885APLNR 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.